Broad Pipeline of Internally Discovered Agents

Lead asset in pivotal trials both globally and in China, additional pivotal programs to start in 2017.        

jietu20170817-192548

* Some indications will not require a non-registrational Phase 2 clinical trial prior to beginning registrational Phase 2 or 3 clinical trials.

** Confirmatory clinical trials post approval are required for accelerated approvals.

1 Entered into a collaboration with Celgene, that has not yet closed, to grant Celgene the rights to develop and commercialize in solid tumors in the United States, European Union, Japan and the rest-of-world outside of Asia.

2 Limited collaboration with Merck KGaA

3 As of July 26, 2017.

 

jietu20170816-214000

* Some indications will not require a non-registrational Phase 2 clinical trial prior to beginning registrational Phase 2 or 3 clinical trials.

** Confirmatory clinical trials post approval are required for accelerated approvals.